Corbus Pharmaceuticals (CRBP) AI Stock Analysis

• Market Cap: $140.60M
• Dividend Yield: N/A
• Average Volume (3M): 503.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: N/A
• EPS Growth: -17.43%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.90
• Shares Outstanding: 17,553,038
• 10 Day Avg. Volume: 744,820
• 30 Day Avg. Volume: 503,638
• PEG Ratio: 0.05
• Price to Book (P/B): 0.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.08
• Enterprise Value/Market Cap: 0.48
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -4.26
• Enterprise Value/Ebitda: -0.98
• 1Y Price Target: $46.00
• Price Target Upside: 474.28% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $9.50 ▲(18.60% Upside)

The score is held back primarily by weak financial performance (no revenue, sizable losses and cash burn) and bearish technical signals (below major moving averages with negative MACD). Offsetting factors include a low-debt balance sheet and positive recent corporate events around pipeline progress and financing that may improve operating runway into upcoming clinical milestones.

Positive Factors

Extended cash runway from financing

A sizable $75M offering materially extends the company’s runway into 2028, reducing near-term funding pressure and allowing management to execute planned registrational and mid-stage trials in 2026. This durable liquidity buffer supports clinical development continuity and strategic options.

Diversified clinical pipeline

Having multiple programs across oncology (CRB-701 ADC, CRB-601) and obesity (CRB-913) lowers single-asset binary risk. Staggered readouts and registrational intent create multiple value-inflection points, improving the long-term probability that at least one program reaches commercialization or partnership.

Low financial leverage

Extremely low leverage reduces solvency and interest-rate risk for a high-burn biotech. With minimal debt obligations, the company can prioritize R&D spend, access equity or partnership financing with greater flexibility, and avoid near-term covenant or refinancing constraints.

Negative Factors

No meaningful revenue base

The company remains purely development-stage with zero product revenue. Long-term sustainability depends on successful trial outcomes or deals; absent commercialization or durable partnerships, continued R&D spending will require repeated external financing, pressuring returns and ownership.

High and persistent cash burn

Sustained negative operating and free cash flows indicate structural cash consumption to fund trials. Even with recent financings, ongoing burn necessitates future funding unless programs reach revenue-generating milestones; this elevates dilution and execution risk over the medium term.

Equity volatility and dilution risk

Historical equity volatility and prior negative equity signal balance-sheet instability during development phases. Combined with repeated 2025 equity raises, this pattern creates a durable risk that future clinical spending or setbacks will require further dilution, affecting long-term shareholder value.

Corbus Pharmaceuticals Business Overview & Revenue Model

Company Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

How the Company Makes Money

Corbus Pharmaceuticals primarily makes money through the development and commercialization of its drug candidates. The company's revenue model involves advancing its drug pipeline through clinical trials, obtaining regulatory approvals, and subsequently partnering with larger pharmaceutical companies for distribution and commercialization. Key revenue streams include milestone payments from strategic partnerships, licensing agreements, and potential sales of its proprietary drugs once approved. Corbus relies on collaborations with other pharmaceutical companies and research institutions to enhance its research capabilities and expedite the development of its therapeutic candidates, which is crucial for generating future revenue.

Corbus Pharmaceuticals Financial Statement Overview

Summary

Financials reflect a development-stage biotech: no meaningful revenue and large ongoing losses (TTM net loss ~-$67.5M) with substantial cash burn (TTM operating cash flow/free cash flow ~-$59.5M). This is partially offset by a currently low-leverage balance sheet (TTM debt-to-equity ~0.02), providing some flexibility despite continued negative returns.

Income Statement

CRBP continues to operate with no meaningful revenue base (revenue is 0 in recent periods, including TTM (Trailing-Twelve-Months)), while losses remain large. TTM (Trailing-Twelve-Months) net loss is about $67.5M and operating losses are similarly heavy, indicating the business is still in a high-burn development phase. A positive is that losses have not consistently worsened year-over-year (2024 net loss improved versus 2023), but profitability remains structurally weak and highly dependent on future commercialization or financing.

Balance Sheet

The balance sheet is a relative strength: leverage is low in the most recent periods (TTM (Trailing-Twelve-Months) debt-to-equity ~0.02, with ~$2.0M debt versus ~$92.1M equity). Assets also meaningfully exceed debt, which provides financial flexibility. The key risk is volatility in equity over time (including negative equity in 2023), and returns on equity are negative in the latest periods due to ongoing losses.

Cash Flow

Cash generation remains weak with persistent cash burn: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both about -$59.5M. While free cash flow improved versus 2024 (strong positive growth rate in the data), the business is still consuming significant cash to fund operations. This keeps funding risk elevated, as continued burn typically requires additional capital raises or partnerships.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	881.71K	3.94M
Gross Profit	-15.89M	-600.00K	0.00	-1.49M	-757.53K	3.94M
EBITDA	-68.87M	-37.74M	-40.10M	-38.73M	-54.35M	-121.12M
Net Income	-67.51M	-40.21M	-44.60M	-55.83M	-45.55M	-111.27M
Balance Sheet
Total Assets	109.51M	155.88M	28.27M	66.31M	107.73M	102.29M
Cash, Cash Equivalents and Short-Term Investments	26.98M	149.06M	20.91M	59.20M	97.65M	85.43M
Total Debt	2.05M	3.24M	20.89M	25.09M	26.59M	26.84M
Total Liabilities	17.37M	13.45M	35.18M	33.32M	38.62M	57.02M
Stockholders Equity	92.15M	142.43M	-6.91M	32.99M	69.11M	45.27M
Cash Flow
Free Cash Flow	-59.51M	-41.79M	-36.10M	-37.56M	-48.24M	-100.17M
Operating Cash Flow	-59.51M	-41.79M	-36.10M	-37.54M	-48.18M	-99.69M
Investing Cash Flow	64.23M	-121.31M	35.64M	30.07M	-73.42M	-484.49K
Financing Cash Flow	2.84M	166.58M	-2.82M	-533.62K	60.82M	154.87M

Corbus Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBP, the sentiment is Negative. The current price of 8.01 is below the 20-day moving average (MA) of 8.47, below the 50-day MA of 9.09, and below the 200-day MA of 9.85, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 39.34 is Neutral, neither overbought nor oversold. The STOCH value of 10.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBP.

Corbus Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BMEA	50 Neutral	$77.07M	-0.46	-209.00%	―	―	40.22%
CRBP	49 Neutral	$140.60M	-1.45	-55.65%	―	―	-17.43%
TCRX	49 Neutral	$54.56M	-0.86	-76.44%	―	-10.03%	11.06%
ATOS	43 Neutral	$45.55M	-1.50	-48.89%	―	―	-9.42%
SAVA	42 Neutral	$94.20M	―	-85.44%	―	―	-505.96%

Corbus Pharmaceuticals Corporate Events

Corbus Updates Corporate Outlook, Highlights Diversified 2026 Pipeline

On January 12, 2026, Corbus Pharmaceuticals updated its corporate presentation to highlight a diversified pipeline and key clinical milestones expected in 2026, underpinned by $173 million in cash, cash equivalents and investments as of November 3, 2025 and a relatively low share count of about 17.6 million common shares outstanding. The materials emphasize CRB-701 as a potentially best-in-class Nectin-4 antibody-drug conjugate with a proprietary design that delivers longer half-life, lower free MMAE exposure and a more convenient dosing regimen than current Nectin-4/MMAE competitors, alongside emerging safety data from a 167-patient dataset presented at ESMO 2025 showing lower rates of high-grade adverse events and peripheral neuropathy versus peer agents, positioning the drug to target high Nectin-4–expressing tumors such as head and neck, cervical and urothelial cancers. Corbus also outlines a 12-week, 240-patient mid-2026 obesity readout for CRB-913 and dose-escalation progress for CRB-601 in αvβ8-enriched solid tumors, signaling an active clinical year that could be pivotal for validating its oncology and metabolic franchises and strengthening its competitive standing in the ADC and obesity drug markets.

The most recent analyst rating on (CRBP) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

Corbus Pharmaceuticals Announces Retirement of Board Member Holmer

On December 12, 2025, Corbus Pharmaceuticals Holdings, Inc. announced that board member Alan Holmer notified the company of his decision to retire and will resign from its Board of Directors effective December 31, 2025. The company stated that Holmer’s departure was not due to any disagreement over its operations, policies, or practices, suggesting an orderly governance transition with no underlying operational or strategic dispute signaled to stakeholders.

The most recent analyst rating on (CRBP) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

Corbus Pharmaceuticals Advances Obesity Treatment with CRB-913

On December 11, 2025, Corbus Pharmaceuticals announced the completion of its Phase 1a study of CRB-913, an oral CB1 inverse agonist for obesity management, and the initiation of a Phase 1b study expected to conclude in summer 2026. The Phase 1a study demonstrated that CRB-913 was safe, well-tolerated, and effective in promoting weight loss, with no serious adverse events reported, marking a significant step forward in Corbus’ obesity treatment research.

The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

Corbus Pharmaceuticals Completes $75 Million Public Offering

Corbus Pharmaceuticals reported its third quarter 2025 financial results, highlighting significant progress in its clinical programs. The company presented promising data for CRB-701 at ESMO 2025, with plans to start a registrational study in mid-2026. Additionally, Corbus completed a $75 million public offering, extending its cash runway into 2028, and is on track to advance its CRB-913 program for obesity treatment by the end of 2025. The financial results showed an increased net loss due to higher clinical development expenses, but the company’s strong cash position supports its operations and future plans.

The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

Corbus Pharmaceuticals Announces $70.5M Public Offering

On October 30, 2025, Corbus Pharmaceuticals announced an underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $70.5 million. The proceeds are intended to fund clinical development and general corporate purposes. The offering, managed by Jefferies and Piper Sandler, is expected to close around November 3, 2025, subject to customary conditions. This move is part of Corbus’ strategy to strengthen its financial position and advance its pipeline in the competitive oncology and obesity sectors.

The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

Corbus Pharmaceuticals Announces Preliminary Q3 Financials

Corbus Pharmaceuticals Holdings, Inc. announced preliminary financial information for the quarter ended September 30, 2025, estimating cash, cash equivalents, and investments at approximately $104.0 million. This figure includes $27.0 million in cash and cash equivalents. The company emphasized that these figures are preliminary and subject to change following financial closing procedures, and stakeholders should not place undue reliance on these estimates.

The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.